NCT05277493招募中不适用
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Hematologic complete response at 3 months
研究概览
简要总结
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years and older
- •newly diagnosed or refractory/relapsed AL amyloidosis
- •treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy
排除标准
- •co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia
结局指标
主要结局
Hematologic complete response at 3 months
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure TechnologyNon-valvular Atrial FibrillationNCT03917563Xijing Hospital1,050
已完成
不适用
Clinical Pathway for Alzheimer's Disease in China (CPAD)Mild Cognitive ImpairmentDementiaAlzheimer's DiseaseNCT01779310Peking University1,024
Unknown
不适用
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing SpondylitisSpondylitis, AnkylosingNCT01901627Peking Union Medical College Hospital400
招募中
不适用
A Registry of AL Amyloidosis (ReAL)AL AmyloidosisNCT04839003Fondazione IRCCS Policlinico San Matteo di Pavia5,000
已完成
不适用
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsAlzheimer DiseaseCognition DisordersNCT02918539Avid Radiopharmaceuticals317